新晋女首富诞生，1400亿

Core Viewpoint - The article highlights the rise of Zhong Huijuan as the new richest woman in China, with a wealth of 141 billion yuan, primarily due to the significant increase in the market value of Hansoh Pharmaceutical, which surged from 90 billion to over 200 billion HKD this year [4][5][7]. Company Overview - Zhong Huijuan is the founder, chairman, and CEO of Hansoh Pharmaceutical, which has transitioned from a generic drug company to an innovative drug enterprise focusing on major disease treatments [7][8]. - The company went public in June 2019 and has seen its stock price increase by over 100% this year, contributing to Zhong's wealth growth of over 60 billion yuan [7][15]. Market Dynamics - The article discusses the broader context of the biopharmaceutical industry, noting a significant surge in wealth among entrepreneurs in the innovative drug sector, particularly in the oncology field [15][16]. - The total value of business development (BD) transactions in China's innovative drug sector reached 63.55 billion USD in the first half of the year, surpassing the total for 2024, indicating a robust market environment [15][16]. Notable Transactions - Hansoh Pharmaceutical recently entered a major licensing agreement with Roche for a targeted antibody-drug conjugate, which includes an upfront payment of 80 million USD and potential milestone payments totaling 1.45 billion USD [7][15]. Industry Trends - The article notes a wave of new wealth in the pharmaceutical sector, with several companies experiencing significant stock price increases, driven by a recovery in the A-share and Hong Kong markets [15][16]. - However, it also mentions emerging concerns as the innovative drug sector has entered a period of adjustment, with some leading companies experiencing notable stock price declines [16].